Knoll Capital Management as of March 31, 2014
Portfolio Holdings for Knoll Capital Management
Knoll Capital Management holds 16 positions in its portfolio as reported in the March 2014 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Medivation | 75.9 | $147M | 2.3M | 64.37 | |
| Ampio Pharmaceuticals | 9.7 | $19M | 3.0M | 6.35 | |
| Alcobra | 6.5 | $13M | 687k | 18.15 | |
| Synthetic Biologics | 1.8 | $3.5M | 1.4M | 2.57 | |
| Keryx Biopharmaceuticals | 1.8 | $3.4M | 200k | 17.04 | |
| Newlink Genetics Corporation | 1.1 | $2.2M | 77k | 28.40 | |
| Northwest Biotherapeutics In (NWBO) | 0.8 | $1.5M | 200k | 7.24 | |
| Inovio Pharmaceuticals | 0.7 | $1.4M | 408k | 3.33 | |
| Merrimack Pharmaceuticals In | 0.4 | $809k | 161k | 5.04 | |
| Galmed Pharmaceuticals | 0.4 | $746k | 65k | 11.48 | |
| Advaxis | 0.4 | $707k | 225k | 3.14 | |
| Nephrogenex | 0.2 | $412k | 50k | 8.24 | |
| ParkerVision | 0.1 | $240k | 50k | 4.80 | |
| Celsus Therapeutics Plc sponsored adr ne | 0.1 | $151k | 23k | 6.49 | |
| Advaxis Inc. w exp 07/15/201 | 0.1 | $141k | 113k | 1.25 | |
| Echo Therapeutics | 0.0 | $86k | 29k | 3.00 |
